SB0066 creates the Health Care Availability and Access Board Act, establishing a new state board and stakeholder council to review prescription drug affordability and, when warranted, set upper payment limits for certain drugs sold or reimbursed in Illinois. The bill is aimed at protecting residents, state and local governments, health plans, providers, and pharmacies from high prescription drug costs. It sets out detailed rules for board membership, conflicts of interest, public meetings, stakeholder input, appeals, reporting, and enforcement.
The board’s review authority is limited to higher-cost or rapidly increasing prescription drugs, including brand-name drugs, biologics, certain biosimilars, and some generic drugs. If the board finds a drug creates an affordability challenge, it must establish an upper payment limit, and for drugs that already have a federal Medicare Maximum Fair Price, the board must adopt that federal price as the state upper payment limit rather than setting a different one. The bill also creates a dedicated fund financed by annual assessments on manufacturers, authorizes the Attorney General to enforce the act, and takes effect 180 days after becoming law.
The bill would add a new chapter to Illinois law and amend the State Finance Act to create the Health Care Availability and Access Board Fund. It would give the new board authority to investigate prescription drug pricing, require public and stakeholder participation in certain decisions, and impose upper payment limits on covered drug purchases and reimbursements in the state. It also affects manufacturers, pharmacies, health plans, and state-regulated payers by potentially limiting what can be charged or reimbursed for selected drugs, while expressly excluding Medicare Part C and D plans from any reimbursement requirement at the upper payment limit.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears strongly pro-consumer and cost-containment oriented. The measure is framed as a prescription drug affordability initiative, with multiple transparency and conflict-of-interest safeguards suggesting an effort to build public trust in the board’s decisions. No opposing arguments are documented in the provided record, but the structure of the bill indicates an intent to balance price controls with stakeholder input and procedural protections.
The most likely points of contention are the board’s authority to impose upper payment limits, the use of manufacturer assessments to fund the board, and the potential impact on pharmaceutical companies, pharmacies, and health plans. The bill also limits the board’s methodology by prohibiting certain cost-effectiveness analyses based on quality-adjusted life years, which may be important to disability advocates and patient groups. Another possible issue is the interaction with federal Medicare pricing and the bill’s rule that state limits must match the Medicare Maximum Fair Price when one exists, which may be seen as either a safeguard against conflict or a constraint on state flexibility.